ContactLegalSearchHome
About
Pipeline
AvalonRX
Partnerships
Investors
Careers
Stock: AVRX
NASDAQ: 1.23 .01
Volume: 1,600
7/3/2008 11:14am ET
Min. 20 minute delay

Overview

Avalon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Our lead product candidate, AVN944, an IMPDH inhibitor, is in Phase II clinical development. Late stage preclinical programs include inhibitors of the Beta-catenin and PLK3 (Aurora/Centrosome) pathways, and discovery programs for inhibitors of the Survivin and Myc pathways. We have partnerships with Merck, AstraZeneca/MedImmune, ChemDiv, Medarex, and Novartis which utilize our proprietary drug discovery and development platform, AvalonRx®.  AvalonRx® is based on large-scale biomarker identification and monitoring to discover and develop therapeutics for pathways that have historically been characterized as "undruggable."

Avalon Pharmaceuticals was established in 1999 and completed its initial public
offering in 2005. The company is headquartered in Germantown, Maryland.